Pharmacologic treatment of acute renal failure in sepsis - SASSiT

Pharmacologic treatment of renal failure De Vriese and Bourgeois 479
olone therapy in unresolving acute respiratory distress syndrome: a randomized
controlled trial. JAMA 1998, 280:159–165.
22 Meduri GU, Tolley EA, Chrousos GP, et al.: Prolonged methylprednisolone
treatment suppresses systemic inflammation in patients with unresolving
acute respiratory distress syndrome: evidence for inadequate endogenous
glucocorticoid secretion and inflammation-induced immune cell resistance to
glucocorticoids. Am J Respir Crit Care Med 2002, 165:983–991.
23 Lebel MH, Freij BJ, Syrogiannopoulos GA, et al.: Dexamethasone therapy for
bacterial meningitis: results of two double-blind, placebo-controlled trials. N
Engl J Med 1988, 319:964–971.
24 de Gans J, van de Beek D: Dexamethasone in adults with bacterial meningitis.
N Engl J Med 2002, 347:1549–1556.
25 Bollaert PE, Charpentier C, Levy B, et al.: Reversal of late septic shock with
supraphysiologic doses of hydrocortisone. Crit Care Med 1998, 26:645–
650.
26 Briegel J, Forst H, Haller M, et al.: Stress doses of hydrocortisone reverse
hyperdynamic septic shock: a prospective, randomized, double-blind, singlecenter
study. Crit Care Med 1999, 27:723–732.
27 Annane D, Sebille V, Charpentier C, et al.: Effect of treatment with low doses
•• of hydrocortisone and fludrocortisone on mortality in patients with septic
shock. JAMA 2002, 288:862–871.
Large randomized, controlled trial demonstrating efficacy of steroid replacement
therapy in sepsis.
28 Keh D, Boehnke T, Weber-Cartens S, et al.: Immunologic and hemodynamic
effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized,
placebo-controlled, crossover study. Am J Respir Crit Care Med 2003,
167:512–520.
29 Conger J, Robinette J, Villar A, et al.: Increased nitric oxide synthase activity
despite lack of response to endothelium-dependent vasodilators in postischemic
acute renal failure in rats. J Clin Invest 1995, 96:631–638.
30 Morrissey JJ, McCracken R, Kaneto H, et al.: Location of an inducible nitric
oxide synthase mRNA in the normal kidney. Kidney Int 1994, 45:998–1005.
31 Yu L, Gengaro PE, Niederberger M, et al.: Nitric oxide: a mediator in rat tubular
hypoxia/reoxygenation injury. Proc Natl Acad Sci USA1994,
91:1691–1695.
32 Shultz PJ, Raij L: Endogenously synthesized nitric oxide prevents endotoxininduced
glomerular thrombosis. J Clin Invest 1992, 90:1718–1725.
33 Spain DA, Wilson MA, Garrison RN: Nitric oxide synthase inhibition exacerbates
sepsis-induced renal hypoperfusion. Surgery 1994, 116:322–330.
34 Booke M, Hinder F, McGuire R, et al.: Nitric oxide synthase inhibition versus
norepinephrine in ovine sepsis: effects on regional blood flow. Shock 1996,
5:362–370.
35 Doursout MF, Kilbourn RG, Hartley CJ, et al.: Effects of N-methyl-L-arginine
on cardiac and regional blood flow in a dog endotoxin shock model. J Crit
Care 2000, 15:22–29.
36 Rosselet A, Feihl F, Markert M, et al.: Selective iNOS inhibition is superior to
norepinephrine in the treatment of rat endotoxic shock. Am J Respir Crit Care
Med 1998, 157:162–170.
37 Cohen RI, Hassell AM, Marzouk K, et al.: Renal effects of nitric oxide in endotoxemia.
Am J Respir Crit Care Med 2001, 164:1890–1895.
38 Petros A, Lamb G, Leone A, et al.: Effects of a nitric oxide synthase inhibitor
in humans with septic shock. Cardiovasc Res 1994, 28:34–39.
39 Avontuur JA, Tutein Nolthenius RP, van Bodegom JW, et al.: Prolonged inhibition
of nitric oxide synthesis in severe septic shock: a clinical study. Crit
Care Med 1998, 26:660–667.
40 Grover R, Zaccardelli D, Colice G, et al.: An open-label dose escalation study
of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride
(546C88), in patients with septic shock. Glaxo Wellcome International Septic
Shock Study Group. Crit Care Med 1999, 27:913–922.
41 Weitzberg E, Lundberg JM, Rudehill A: Elevated plasma levels of endothelin
in patients with sepsis syndrome. Circ Shock 1991, 33:222–227.
42 Mitaka C, Hirata Y, Yokoyama K, et al.: Improvement of renal dysfunction in
dogs with endotoxemia by a nonselective endothelin receptor antagonist. Crit
Care Med 1999, 27:146–153.
43 Chin A, Radhakrishnan J, Fornell L, et al.: Effects of tezosentan, a dual endothelin
receptor antagonist, on the cardiovascular and renal systems of neonatal
piglets during endotoxic shock. J Pediatr Surg 2002, 37:482–487.
44 Morise Z, Ueda M, Aiura K, et al.: Pathophysiologic role of endothelin-1 in
renal function in rats with endotoxin shock. Surgery 1994, 115:199–204.
45 Oldner A, Wanecek M, Goiny M, et al.: The endothelin receptor antagonist
bosentan restores gut oxygen delivery and reverses intestinal mucosal acidosis
in porcine endotoxin shock. Gut 1998, 42:696–702.
46 Gardiner SM, March JE, Kemp PA, et al.: Effects of the novel selective endothelin
ET(A) receptor antagonist, SB 234551, on the cardiovascular responses
to endotoxaemia in conscious rats. Br J Pharmacol 2001,
133:1371–1377.
47 Allgren RL, Marbury TC, Rahman SN, et al.: Anaritide in acute tubular necrosis.
Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997,
336:828–834.
48 Schramm L, Heidbreder E, Lukes M, et al.: Endotoxin-induced acute renal
failure in the rat: effects of urodilatin and diltiazem on renal function. Clin
Nephrol 1996, 46:117–124.
49 Hiki N, Mimura Y: Atrial natriuretic peptide has no potential to protect against
endotoxin-induced acute renal failure in the absence of renal nerves. Endocr
J 1998, 45:75–81.
50 Rahman SN, Kim GE, Mathew AS, et al.: Effects of atrial natriuretic peptide in
clinical acute renal failure. Kidney Int 1994, 45:1731–1738.
51 Lewis J, Salem MM, Chertow GM, et al.: Atrial natriuretic factor in oliguric
acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney
Dis 2000, 36:767–774.
52 Herbert MK, Ginzel S, Muhlschlegel S, et al.: Concomitant treatment with
urodilatin (ularitide) does not improve renal function in patients with acute
renal failure after major abdominal surgery—a randomized controlled trial.
Wien Klin Wochenschr 1999, 111:141–147.
53 Meyer M, Pfarr E, Schirmer G, et al.: Therapeutic use of the natriuretic peptide
ularitide in acute renal failure. Ren Fail 1999, 21:85–100.
54 Rinder CS, Fontes M, Mathew JP, et al., Multicenter Study of Perioperative
Ischemia Research Group: Neutrophil CD11b upregulation during cardiopulmonary
bypass is associated with postoperative renal injury. Ann Thorac Surg
2003, 75:899–905.
55 Kelly KJ, Williams WW Jr, Colvin RB, et al.: Antibody to intercellular adhesion
molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci U
S A 1994, 91:812–816.
56 Kelly KJ, Williams WW Jr, Colvin RB, et al.: Intercellular adhesion molecule-
1-deficient mice are protected against ischemic renal injury. J Clin Invest
1996, 97:1056–1063.
57 Haller H, Dragun D, Miethke A, et al.: Antisense oligonucleotides for ICAM-1
attenuate reperfusion injury and renal failure in the rat. Kidney Int 1996,
50:473–480.
58 Rabb H, Mendiola CC, Dietz J, et al.: Role of CD11a and CD11b in ischemic
acute renal failure in rats. Am J Physiol 1994, 267:F1052–F1058.
59 Lowell CA, Berton G: Resistance to endotoxic shock and reduced neutrophil
migration in mice deficient for the Src-family kinases Hck and Fgr. Proc Natl
Acad Sci USA1998, 95:7580–7584.
60 Hayashi H, Imanishi N, Ohnishi M, et al.: Sialyl Lewis X and anti-P-selectin
antibody attenuate lipopolysaccharide-induced acute renal failure in rabbits.
Nephron 2001, 87:352–360.
61 Matsukawa A, Lukacs NW, Hogaboam CM, et al.: Mice genetically lacking
• endothelial selectins are resistant to the lethality in septic peritonitis. Exp Mol
Pathol 2002, 72:68–76.
Demonstrates beneficial effects of inhibition of leukocyte recruitment on both renal
dysfunction and mortality in an experimental model of septic ARF.
62 Root RK, Lodato RF, Patrick W, et al., Pneumonia Sepsis Study Group: Multicenter,
double-blind, placebo-controlled study of the use of filgrastim in patients
hospitalized with pneumonia and severe sepsis. Crit Care Med 2003,
31:367–373.
63 Welty-Wolf KE, Carraway MS, Miller DL, et al.: Coagulation blockade prevents
sepsis-induced respiratory and renal failure in baboons. Am J Respir
Crit Care Med 2001, 164:1988–1996.
64 Carraway MS, Welty-Wolf KE, Miller DL, et al.: Blockade of tissue factor:
treatment for organ injury in established sepsis. Am J Respir Crit Care Med
2003, 167:1200–1209.
Experimental evidence for the efficacy of late treatment with TFPI in sepsis.
65 Healy DP: New and emerging therapies for sepsis. Ann Pharmacother 2002,
36:648–654.
66 Warren HS, Suffredini AF, Eichacker PQ, et al.: Risks and benefits of activated
protein C treatment for severe sepsis. N Engl J Med 2002, 347:1027–
••
1030.
Critical discussion of the value of APC treatment in sepsis.
67 Warren BL, Eid A, Singer P, et al., KyberSept Trial Study Group: Caring for